Cell signaling refers to the communication processes that trigger cellular activities and coordinate cellular actions. Irregularities and errors in cell signaling are responsible for diseases like cancer, and many other autoimmune diseases, like diabetes. Cell signaling is a major field in modern medical practice and diagnosis.
The Cell Signaling market growth is driven by the increasing incidence of chronic diseases, growing funding for cell-based research, and technological advancements in cell-based research instruments.
Growing funding from the governments and private agencies for cell-based research is expected to drive the global cell signaling market growth.
Cell-based research such as cell signaling, stem cell research gain importance due to the increasing support from government and various private agencies across the world. For instance, according to the data available on the National Institutes of Health (NIH) portal, an estimated USD 1,626 million was granted for stem cell research in 2017. In contrast, the actual fund grants for stem cell research in 2018 amounted to USD 1,748 million.
Similar increments in funding grants were observed for research in embryonic stem cells and induced pluripotent stem cells. Similar positive trends in the increment of fund grants have been observed in the European Union for cell-based research. Consequently, the increasing participation of the government in the development of cell-based research, in the form of incremental funding, is expected to drive the growth of the market.
The increasing incidence of chronic diseases is expected to drive the global cell signaling market growth.
The growing prevalence of these chronic diseases worldwide is driving the market to grow. For instance, according to International Diabetes Federation (IDF), in 2019, approximately 463 people were living with diabetes, and it is estimated that the number is anticipated to grow to 700 million by 2045. Cancer is a leading cause of burden globally. According to the World Health Organization (WHO), worldwide death stats of cancer is projected to reach over 13 million by 2030.
North America region holds the largest market share of global Cell Signaling Market
North America is found to hold a major share of the cell signaling market and is expected to show a similar trend over the forecast period, without significant fluctuations. The cell signaling market is expected to witness numerous growth opportunities during the pandemic, with cell signaling pathways being utilized as experimental virology platforms to study the immune responses and infectivity of SARS-CoV-2. Most of the major players have been involved in R&D activities regarding cell signaling pathways.
The mortality in most COVID-19 patients is due to the presence of a cytokine storm induced by the virus. The excessive production of these proinflammatory cytokines leads to acute respiratory distress syndrome aggravation and widespread tissue damage, which results in multi-organ failure and death. Thus, targeting cell signaling pathways such as cytokines during the management of COVID-19 may lead to the reduction of the mortality rate and improved outcomes. This is likely to have a positive impact on the market studied.
Competitive Landscape
The global Cell signaling market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Beckman Coulter Inc. (Danaher), Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Cell Signaling Technology Inc., Merck KGaA, PerkinElmer Inc., Promega Corporation, Qiagen NV, and Thermo Fischer Scientific Inc, Beijing Boshumei Biotechnology Co., Ltd (PRC), RayBiotech Life, Inc. (PRC), Novus Biologicals, LLC (PRC), Xiamen Life Interconnect Technology Co., Ltd. (PRC).
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, in 2020, Beckman Coulter Life Sciences launched the DxFLEX, Europe’s first CE-IVD, 13-color clinical flow cytometry system. The sensitivity and resolution of the DxFLEX expand laboratory testing capabilities, especially those focusing on user-defined assays.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
